Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 54 results.
User Information
Export Records
  1. 1.   A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma
  2. Liu, Jinping; Tang, Wei; Budhu, Anuradha; Forgues, Marshonna; Hernandez, Maria O; Candia, Julián; Kim, Yujin; Bowman, Elise D; Ambs, Stefan; Zhao,Yongmei; Tran,Bao; Wu,Xiaolin; Koh, Christopher; Surana, Pallavi; Liang, T Jake; Guarnera, Maria; Mann, Dean; Rajaure, Manoj; Greten, Tim F; Wang, Zhanwei; Yu, Herbert; Wang, Xin Wei
  3. Cell. 2020, JUL 23; 182(2): 317-+.
  1. 2.   Nonhuman primate models of human viral infections
  2. Estes, Jake; Wong, Scott W.; Brenchley, Jason M.
  3. NATURE REVIEWS IMMUNOLOGY. 2018, Jun; 18(6): 390-404.
  1. 3.   An overview of enzymatic reagents for the removal of affinity tags
  2. Waugh, D. S.
  3. Protein Expression and Purification. 2011, Dec; 80(2): 283-293.
  1. 4.   KIR2DL2 Enhances Protective and Detrimental HLA Class I-Mediated Immunity in Chronic Viral Infection
  2. al Basatena, N. K. S.; MacNamara, A.; Vine, A. M.; Thio, C. L.; Astemborski, J.; Usuku, K.; Osame, M.; Kirk, G. D.; Donfield, S. M.; Goedert, J. J.; Bangham, C. R. M.; Carrington, M.; Khakoo, S. I.; Asquith, B.
  3. Plos Pathogens. 2011, Oct; 7(10): 12.
  1. 5.   In Vivo Consequences of Liver-Specific Interleukin-22 Expression in Mice: Implications for Human Liver Disease Progression
  2. Park, O.; Wang, H.; Weng, H. L.; Feigenbaum, L.; Li, H.; Yin, S.; Ki, S. H.; Yoo, S. H.; Dooley, S.; Wang, F. S.; Young, H. A.; Gao, B.
  3. Hepatology. 2011, Jul; 54(1): 252-261.
  1. 6.   Twice-weekly pegylated interferon-alpha-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
  2. Murphy, A. A.; Herrmann, E.; Osinusi, A. O.; Wu, L.; Sachau, W.; Lempicki, R. A.; Yang, J.; Chung, T. L.; Wood, B. J.; Haagmans, B. L.; Kottilil, S.; Polis, M. A.
  3. Aids. 2011, Jun; 25(9): 1179-1187.
  1. 7.   TLR-based immune adjuvants
  2. Steinhagen, F.; Kinjo, T.; Bode, C.; Klinman, D. M.
  3. Vaccine. 2011, Apr; 29(17): 3341-3355.
  1. 8.   Possession of HLA Class II DRB1*1303 Associates with Reduced Viral Loads in Chronic HIV-1 Clade C and B Infection
  2. Julg, B.; Moodley, E. S.; Qi, Y.; Ramduth, D.; Reddy, S.; Mncube, Z.; Gao, X. J.; Goulder, P. J.; Detels, R.; Ndung'u, T.; Walker, B. D.; Carrington, M.
  3. Journal of Infectious Diseases. 2011, Mar; 203(6): 803-809.
  1. 9.   KIR Polymorphisms Modulate Peptide-Dependent Binding to an MHC Class I Ligand with a Bw6 Motif
  2. Colantonio, A. D.; Bimber, B. N.; Neidermyer, W. J.; Reeves, R. K.; Alter, G.; Altfeld, M.; Johnson, R. P.; Carrington, M.; O'Connor, D. H.; Evans, D. T.
  3. Plos Pathogens. 2011, Mar; 7(3): 13.
  1. 10.   HCV in Peripheral Blood Mononuclear Cells Are Predominantly Carried on the Surface of Cells in HIV/HCV Co-Infected Individuals
  2. Natarajan, V.; Kottilil, S.; Hazen, A.; Adelsberger, J.; Murphy, A. A.; Polis, M. A.; Kovacs, J. A.
  3. Journal of Medical Virology. 2010, Dec; 82(12): 2032-2037.
  1. 11.   Crystal Structure of Human Interferon-lambda 1 in Complex with Its High-Affinity Receptor Interferon-lambda R1
  2. Miknis, Z. J.; Magracheva, E.; Li, W.; Zdanov, A.; Kotenko, S. V.; Wlodawer, A.
  3. Journal of Molecular Biology. 2010, Dec; 404(4): 650-664.
  1. 12.   In the Absence of HCV Infection, Interferon Stimulated Gene Expression in Liver Is Not Associated With IL28B Genotype
  2. Shebl, F. M.; Maeder, D.; Shao, Y. W.; Prokunina-Olsson, L.; Schadt, E. E.; O'Brien, T. R.
  3. Gastroenterology. 2010, Oct; 139(4): 1422-1424.
  1. 13.   Identification of sequence polymorphism in the D-Loop region of mitochondrial DNA as a risk factor for hepatocellular carcinoma with distinct etiology
  2. Zhang, R. X.; Zhang, F. B.; Wang, C. J.; Wang, S. X.; Shiao, Y. H.; Guo, Z. J.
  3. Journal of Experimental & Clinical Cancer Research. 2010, Sep; 29: 7.
  1. 14.   Elevated Systemic Levels of Inflammatory Cytokines in Older Women with Persistent Cervical Human Papillomavirus Infection
  2. Kemp, T. J.; Hildesheim, A.; Garcia-Pineres, A.; Williams, M. C.; Shearer, G. M.; Rodriguez, A. C.; Schiffman, M.; Burk, R.; Freer, E.; Bonilla, J.; Herrero, R.; Pinto, L. A.
  3. Cancer Epidemiology Biomarkers & Prevention. 2010, Aug; 19(8): 1954-1959.
  1. 15.   Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2a in HIV-1-Monoinfected Participants: A Phase II Clinical Trial
  2. Asmuth, D. M.; Murphy, R. L.; Rosenkranz, S. L.; Lertora, J. J. L.; Kottilil, S.; Cramer, Y.; Chan, E. S.; Schooley, R. T.; Rinaldo, C. R.; Thielman, N.; Li, X. D.; Wahl, S. M.; Shore, J.; Janik, J.; Lempicki, R. A.; Simpson, Y.; Pollard, R. B.; Tea, A. C. T. G. A.
  3. Journal of Infectious Diseases. 2010, Jun 1; 201(11): 1686-1696.
  1. 16.   Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology
  2. Wang, S. S.; Abdou, A. M.; Morton, L. M.; Thomas, R.; Cerhan, J. R.; Gao, X. J.; Cozen, W.; Rothman, N.; Davis, S.; Severson, R. K.; Bernstein, L.; Hartge, P.; Carrington, M.
  3. Blood. 2010, Jun; 115(23): 4820-4823.
  1. 17.   FDA guidance on prophylactic DNA vaccines: Analysis and recommendations
  2. Klinman, D. M.; Klaschik, S.; Tross, D.; Shirota, H.; Steinhagen, F.
  3. Vaccine. 2010, Apr; 28(16): 2801-2805.
  1. 18.   Clinical Use of Interferon-gamma
  2. Miller, C. H. T.; Maher, S. G.; Young, H. A.; Donnelly, R. P.
  3. Cytokine Therapies: Novel Approaches for Clinical Indications. 2009; 1182 : 69-79.
  1. 19.   High Specific Infectivity of Plasma Virus from the Pre-Ramp-Up and Ramp-Up Stages of Acute Simian Immunodeficiency Virus Infection
  2. Ma, Z. M.; Stone, M.; Piatak, M.; Schweighardt, B.; Haigwood, N. L.; Montefiori, D.; Lifson, J. D.; Busch, M. P.; Miller, C. J.
  3. Journal of Virology. 2009 83(7): 3288-3297.
  1. 20.   Protective HLA Class I Alleles That Restrict Acute-Phase CD8(+) T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1
  2. Wang, Y.; Li, B.; Carlson, J. M.; Streeck, H.; Gladden, A. D.; Goodman, R.; Schneidewind, A.; Power, K. A.; Toth, I.; Frahm, N.; Alter, G.; Brander, C.; Carrington, M.; Walker, B. D.; Altfeld, M.; Heckerman, D.; Allen, T. M.
  3. Journal of Virology. 2009 83(4): 1845-1855.
  1. 21.   Pyrosequencing of small non-coding RNAs in HIV-1 infected cells: evidence for the processing of a viral-cellular double-stranded RNA hybrid
  2. Yeung, M. L.; Bennasser, Y.; Watashi, K.; Le, S. Y.; Houzet, L.; Jeang, K. T.
  3. Nucleic Acids Research. 2009 37(19): 6575-6586.
  1. 22.   Seroprevalence and risk factors for human herpesvirus 8 infection, rural egypt
  2. Mbulaiteye, S. M.; Pfeiffer, R. M.; Dolan, B.; Tsang, V.; Noh, J.; Mikhail, N.; Abdel-Hamid, M.; Hashem, M.; Whitby, D.; Strickl, G. T.; Goedert, J. J.
  3. Emerging Infectious Diseases. 2008 14(4): 586-591.
  1. 23.   Effects of o-aminoazotoluene on liver regeneration and p53 activation in mice susceptible and resistant to hepatocarcinogenesis
  2. Timofeeva, O. A.; Eremeev, A. V.; Goloshchapov, A.; Kalashnikova, E.; Ilnitskaya, S.; Setkov, N. A.; Kobzev, V.; Buzard, G. S.; Filipenko, M. L.; Kaledin, V.; Merkulova, T. I.
  3. Toxicology. 2008 254(1-2): 91-96.
  1. 24.   Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients
  2. Neumann, A. U.; Polis, M. A.; Rozenberg, L.; Jackson, J. O.; Reitano, K. N.; McLaughlin, M.; Koratich, C.; Dewar, R. L.; Masur, H.; Haagmans, B. L.; Kottilil, S.
  3. Aids. 2007, Sep; 21(14): 1855-1865.
  1. 25.   Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine
  2. Mikszta, J. A.; Dekker, J. P.; Harvey, N. G.; Dean, C. H.; Brittingham, J. M.; Huang, J.; Sullivan, V. J.; Dyas, B.; Roy, C. J.; Ulrich, R. G.
  3. Infection and Immunity. 2006, Dec; 74(12): 6806-6810.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel